Alerta

SYSTEM AND METHOD FOR DETECTING PRESSURE INDUCED SENSOR ATTENUATIONS (PISAS) OF CONTINUOUS GLUCOSE MONITORING (CGM)

Resumen de: AU2023372542A1

Embodiments can relate to a system for automatically detecting sensor compression in continuous glucose monitoring including at least one sensor and at least one processor in communication with the at least one sensor, the at least one processor executing at least two machine learning models, wherein the at least one processor is programmed or configured to cause the processor to receive, from the at least one sensor, measurement data including at least one time series of blood glucose (BG) measurements measured by the at least one sensor, determine that the at least one time series of BG measurements is a candidate series including a compression artifact using a first machine learning model, and generate, using a second machine learning model, a signal output indicating that the at least one time series of BG measurements was obtained while the at least one sensor was subject to compression.

SYSTEM AND METHOD FOR DETECTING SENSOR COMPRESSION OF CONTINUOUS GLUCOSE MONITORING (CGM) SENSORS

Resumen de: AU2023372535A1

Embodiments can relate to systems and methods for automatically detecting sensor compression in continuous glucose monitoring in real time. A system may include at least one sensor and at least one processor in communication with the at least one sensor. The at least one processor is programmed or configured to cause the processor to retrieve first measurement data including at least one time series of blood glucose (BG) measurements, the at least one time series being measured by the at least one sensor while not subject to compression; receive, from the at least one sensor, second measurement data including at least one BG measurement; determine a clearance value between BG measurements based on the first measurement data and the second measurement data; and generate a signal output indicating that the at least one sensor is subject to compression based on the clearance value between BG measurements exceeding a predefined threshold.

BODY ATTACHMENT UNIT FOR CONTINUOUS BLOOD GLUCOSE MONITORING

Resumen de: EP4545003A2

The present invention relates to a body attachment unit for continuous blood glucose monitoring, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and activation can occur in a stabilized state, and thereby allowing more accurate blood glucose monitoring.

ADJUSTING INSULIN DELIVERY RATES

Resumen de: EP4545005A2

The present disclosure relates to a diabetes management system and methods related to the same. The system includes a pump device and a controller. The controller receives blood glucose data, determines basal insulin dosages based on stored baseline basal rates, controls insulin dispensation based on the determined basal insulin dosages, modifies a target blood glucose levels, receives a temporary override indicating a user preference to reduce the likelihood of a hypoglycemic or hyperglycemic event, determines a temporary target blood glucose level accordingly, and controls dispensation according to the temporary target blood glucose level. The controller can also calculate a probability that a blood glucose level crosses a threshold, determine a target blood glucose level based on a fear of hypoglycemia index and the calculated probability, determine insulin delivery information according to the target blood glucose level, and control dispensation accordingly.

WEARABLE AUTOMATED MEDICATION DELIVERY SYSTEM

Resumen de: EP4546365A2

Systems and methods for automatically delivering medication to a user. A sensor coupled to a user can collect information regarding the user. A controller can use the collected information to determine an amount of medication to provide the user. The controller can instruct a drug delivery device to dispense the medication to the user. The drug delivery device can be a wearable insulin pump that is directly coupled to the user. The controller can be part of or implemented in a cellphone. A user can be required to provide a confirmation input to allow a determined amount of insulin to be provided to the user based on detected glucose levels of the user. The sensor, controller, and drug delivery device can communicate wirelessly.

METHOD FOR DETECTING RISK OF DIABETES, ELECTRONIC DEVICE, AND SYSTEM

Resumen de: EP4545001A1

A diabetes risk detection method, an electronic device, and a system are disclosed and are applied to the field of terminal technologies, to resolve a problem in the conventional technology that an obtained diabetes risk detection result is inaccurate when time for collecting a PPG signal is short. The method includes: obtaining first data and second data, where the first data includes a photoplethysmography PPG signal obtained via a PPG sensor, and the second data includes one or more of the following: diet data, exercise data, physical symptom data, drug use data, sleep data, and emotion data; determining a diabetes risk detection result based on the first data and the second data; and finally outputting the diabetes risk detection result to prompt a user with a health status.

ENSEMBLE OF PARTITIONED SENSOR GLUCOSE MODELS

Resumen de: EP4545002A1

A processor-implemented method includes receiving sensor measurement data from a glucose sensor; selecting, based on the sensor measurement data, a first regional sensor glucose (SG) model from a first plurality of regional SG models for respective regions of a first plurality of regions of an input parameter space associated with the sensor measurement data, and a second regional SG model from a second plurality of regional SG models for respective regions of a second plurality of regions of the input parameter space; estimating a first SG value and a second SG value using the first regional SG model and the second regional SG model, respectively; and determining a predicted SG value based on a combination of the first SG value and the second SG value. The input parameter space is partitioned into the first plurality of regions and the second plurality of regions using different partition schemes.

AUTOMATED MEDICAMENT DELIVERY SYSTEM MANAGEMENT WITHOUT ANALYTE MEASUREMENTS

Resumen de: EP4546359A2

A medicament delivery system, process and techniques are provided. The medicament delivery system may include a wearable medicament delivery device, a memory storing programming instructions, and a processor. The processor may be operable to execute the programming instructions, which cause the processor to receive an available medicament delivery history of a user, and determine whether the available medicament delivery history spans an extent of time greater than a first glucose history duration. The processor, in response to a determination that the extent of time spanned by the available medicament delivery history is greater than the first glucose history duration, determines an average daily medicament delivered. The processor calculates a trust value of the available medicament delivery history, and utilizes the trust value to determine a total daily medicament value of the user.

IMPLANTABLE GLUCOSE MONITOR

Resumen de: EP4545007A1

Implantable device for measuring the glucose concentration of a body fluid when implanted, the device comprising a glucose measurement unit, the glucose measurement unit comprising a light source configured to emit light towards a light transmissive part of a housing of the device, the device further comprising an optical sensor configured to detect light returned through the transmissive part from the light source, and output an electrical signal based on the detected light, and a wireless communication module configured to wirelessly communicate with an external wireless communication device, wherein the wireless communication module is configured to wirelessly transmit a signal based on the electrical signal to the external wireless communication device.

SYSTEMS AND METHODS FOR PROVIDING SENSITIVE AND SPECIFIC ALARMS

Resumen de: EP4545004A2

Systems and methods for providing sensitive and specific alarms indicative of glycemic condition are provided herein. In an embodiment, a method of processing sensor data by a continuous analyte sensor includes: evaluating sensor data using a first function to determine whether a real time glucose value meets a first threshold; evaluating sensor data using a second function to determine whether a predicted glucose value meets a second threshold; activating a hypoglycemic indicator if either the first threshold is met or if the second threshold is predicted to be met; and providing an output based on the activated hypoglycemic indicator.

DEVICES AND TECHNIQUES FOR ULTRASOUND THERAPY VIA A DIALYSIS SYSTEM

Resumen de: WO2025085172A1

A dialysis-ultrasound system is described that includes an ultrasound therapy device integrated with a catheter to incorporate ultrasound therapy into a dialysis system. The ultrasound device may be or may include a high-intensity focused ultrasound (HIFU) device or peripheral focused ultrasound stimulation (pFUS) device. The ultrasound therapy may target the liver, for example, to treat diabetes. In one example, a system includes a catheter configured to be arranged within the peritoneal cavity of a patient for peritoneal dialysis (PD), and an ultrasound device configured to emit ultrasound waves. The ultrasound device is integrated with the catheter and is arranged on the catheter to be implanted within the peritoneal cavity of the patient to provide ultrasound therapy to a target region of the patient. Other embodiments are described.

Biometric Wearable Device (e.g. Finger Ring or Smart Watch) with Optical Sensors and Scanning Light Beams

Resumen de: US2025127439A1

A biometric wearable device (e.g. finger ring or smart watch) has optical sensors to measure body oxygenation level, hydration level, glucose level, heart rate, heart rate variability, and/or blood pressure. Light from light emitters is transmitted through body tissue and changes in the light are analyzed. The angles and/or vectors along which the light is transmitted through body tissue can be automatically changed by the device in order to scan different tissue regions and/or different tissue depths.

BLOOD GLUCOSE MEASUREMENT DEVICE AND METHOD FOR MANAGING BLOOD GLUCOSE MEASUREMENT DATA USING THE SAME

Resumen de: US2025127434A1

A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; a storage unit that includes a plurality of storage areas and stores the blood glucose measurement data in the plurality of storage areas; and a communication unit that transmits the blood glucose measurement data stored in at least one of the plurality of storage areas to an external device.

AUTOMATED MEDICAMENT DELIVERY SYSTEM ADJUSTMENTS WHEN TAKING A PHARMACEUTICAL

Resumen de: US2025127993A1

Disclosed are methods, techniques, systems, and devices that are operable to compensate for the effects of pharmaceuticals on a user's analyte measurement values, such as glucose levels and/or ketone levels. The disclosed system is configured to enable medicament delivery application to enter a pharmaceutical mode. While in pharmaceutical mode, the medicament delivery application is operable to adjust medicament delivery constraints and other settings used by the medicament delivery application to respond to the effects of the pharmaceutical on the user's analyte measurement values.

INSULIN FORMULATIONS AND USES IN INFUSION DEVICES

Resumen de: US2025127861A1

Embodiments of the present disclosure provide insulin formulations having a near neutral pH and improved pharmacokinetic/pharmacodynamic properties, and uses in insulin infusion devices that may provide extended infusion period up to 7-14 days. Also provided are systems for administering insulin, the system may include a first reservoir, a second reservoir, an insulin pump configured to administer contents of the first reservoir or the second reservoir, and one or more hardware processors in communication with the insulin pump.

BLOOD GLUCOSE SENSING SYSTEM

Resumen de: US2025127435A1

A blood glucose sensing system includes a plurality of physiological sensors. The system can estimate blood glucose based on discrete invasive blood glucose estimates from a blood sample, discrete noninvasive blood glucose estimates derived from optical sensors, and continuously-calculated blood glucose estimates derived from a nonlinear state-space model of glucose and insulin reactions within a human body. The state-space model has user-entered values corresponding to their insulin and meal intake. The user's blood glucose is estimated from a combination of the discrete invasive blood glucose estimates, the discrete noninvasive blood glucose estimates and the continuously-calculated blood glucose estimate.

AUTOMATED MEDICAMENT DELIVERY SYSTEM MANAGEMENT WITHOUT ANALYTE MEASUREMENTS

Resumen de: US2025132007A1

A medicament delivery system, process and techniques are provided. The medicament delivery system may include a wearable medicament delivery device, a memory storing programming instructions, and a processor. The processor may be operable to execute the programming instructions, which cause the processor to receive an available medicament delivery history of a user, and determine whether the available medicament delivery history spans an extent of time greater than a first glucose history duration. The processor, in response to a determination that the extent of time spanned by the available medicament delivery history is greater than the first glucose history duration, determines an average daily medicament delivered. The processor calculates a trust value of the available medicament delivery history, and utilizes the trust value to determine a total daily medicament value of the user.

ARRANGEMENT FOR THE OPERATION OF A BIOSENSOR AND SYSTEM FOR THE DETERMINATION OF A GLUCOSE CONTENT IN BLOOD

Resumen de: US2023011856A1

An arrangement for operating a biosensor emitting radiation includes an excitation light source, which generates at least one excitation radiation for the biosensor; a coupling fiber, at the entry surface of which the excitation radiation is coupled in; an optical Y-coupler, including an excitation arm, which is connected to the exit surface of the coupling fiber, a detector arm, which is connected to an optical detector, and a sensor foot, which can be connected to the biosensor. The excitation arm has a conical shape. The radiation axis of the excitation arm includes an angle in the range of 5° to 70° with the main radiation axis of the detector arm. The diameter of the excitation arm at the connecting point to the detector arm is less than two thirds the diameter of the detector arm. An arrangement for determining the glucose content blood is also provided.

METHOD AND SYSTEM OF PENALIZATION FOR MODEL PREDICTIVE CONTROL IN AUTOMATED INSULIN DELIVERY

Resumen de: AU2023377269A1

A method, system, and computer-readable medium are provided for an Automated Insulin Delivery (AID) system in which Model Predictive Control (MPC) thereof implements weighting of glucose target error relative to corresponding predicted blood glucose (BG) levels according to insulin on board (IOB). Accordingly, basal insulin infusion and available additional bolusing each in connection with glycemic disturbances such as unannounced meals can be proximally administered to maintain time in range (TIR) without incurring insulin stacking.

HEALTH-MONITORING DEVICE WIT VCSEL

Resumen de: US2025127429A1

A glucose detection or monitoring system that includes a VCSEL laser with one or more active regions having quantum wells and barrier. The active regions are surrounded by one or more p-n junctions. The one or more active regions can include a selected shape structure, and one or more tunnel junctions (TJ). One or more apertures are provided with the selected shape structure, one or more buried tunnel junctions (BTJ) or oxide confine apertured, additional TJ's, planar structures and or additional BTJ's created during a regrowth process that is independent of a first growth process with a VCSEL output determined in response to a monitoring application of the VCSEL, the VCSEL having an HCG grating and a bottom DBR. A housing of a wearable device interior houses the VCSEL laser.

BLOOD GLUCOSE MEASUREMENT DEVICE AND METHOD FOR MANAGING BLOOD GLUCOSE MEASUREMENT DATA USING THE SAME

Resumen de: US2025127433A1

A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; and a storage unit that stores the blood glucose measurement data, wherein the control unit stores the preset first verification data in the storage unit, and stores the blood glucose measurement data in the storage unit continuously to the first verification data.

SYSTEMS AND METHODS FOR PROCESSING SENSOR DATA

Resumen de: US2025132008A1

Systems and methods for processing sensor data are provided. In some embodiments, systems and methods are provided for calibration of a continuous analyte sensor. In some embodiments, systems and methods are provided for classification of a level of noise on a sensor signal. In some embodiments, systems and methods are provided for determining a rate of change for analyte concentration based on a continuous sensor signal. In some embodiments, systems and methods for alerting or alarming a patient based on prediction of glucose concentration are provided.

NON-INVASIVE BLOOD GLUCOSE MONITORING DEVICE WITH WEARING FIT DETECTION FUNCTION

Resumen de: US2025127431A1

The invention provides a non-invasive blood glucose monitoring device with a wearing fit detection function, comprising a substrate, a blood glucose monitoring module, an optical feedback sensing module and at least one light-blocking wall. The substrate defines a first setting area for disposing the blood glucose monitoring module and a second setting area for disposing the optical feedback sensing module. The second setting area is between an edge of the substrate and the first setting area. The optical feedback sensing module includes at least one light-emitting element and at least one light-receiving element. Each light-emitting element emits a light signal corresponding to at least one specific wavelength, and each light-receiving element receives the light signal corresponding to the at least one specific wavelength, after being reflected, as a basis for determining the wearing fit. The at least one light-blocking wall is located between the first setting area and the second setting area.

CONTINUOUS BLOOD GLUCOSE MEASUREMENT APPARATUS

Resumen de: US2025127436A1

The present disclosure relates to a continuous glucose monitoring device, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work for a user in attaching the body attachment unit to a body and allowing attachment of the body attachment unit to the body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter and allowing easier maintenance. In addition, the continuous glucose monitoring device is activated by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and the continuous glucose monitoring device can be activated in a stabilized state, and thereby can monitor blood glucose more accurately.

GLUCOSE MONITORING SYSTEM

Nº publicación: US2025127432A1 24/04/2025

Solicitante:

CIRRUS LOGIC INT SEMICONDUCTOR LTD [GB]
Cirrus Logic International Semiconductor Ltd